Amedisys (AMED) vs. Its Peers Head to Head Review

Amedisys (NASDAQ:AMED) is one of 26 publicly-traded companies in the “MED – OUTP/HM CRE” industry, but how does it weigh in compared to its rivals? We will compare Amedisys to similar businesses based on the strength of its profitability, risk, institutional ownership, analyst recommendations, valuation, dividends and earnings.

Insider & Institutional Ownership

94.4% of Amedisys shares are owned by institutional investors. Comparatively, 71.8% of shares of all “MED – OUTP/HM CRE” companies are owned by institutional investors. 2.1% of Amedisys shares are owned by insiders. Comparatively, 9.4% of shares of all “MED – OUTP/HM CRE” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for Amedisys and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amedisys	0	3	1	0	2.25
Amedisys Competitors	108	902	1364	57	2.56

Amedisys presently has a consensus price target of $100.75, indicating a potential upside of 4.80%. As a group, “MED – OUTP/HM CRE” companies have a potential upside of 30.64%. Given Amedisys’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Amedisys has less favorable growth aspects than its rivals.

Profitability

This table compares Amedisys and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amedisys	3.79%	12.52%	7.01%
Amedisys Competitors	-12.27%	-0.50%	-4.12%

Earnings & Valuation

This table compares Amedisys and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Amedisys	$2.35 billion	$43.23 million	35.48
Amedisys Competitors	$3.78 billion	$179.91 million	20.03

Amedisys’ rivals have higher revenue and earnings than Amedisys. Amedisys is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Amedisys has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Amedisys’ rivals have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.

Summary

Amedisys rivals beat Amedisys on 8 of the 13 factors compared.

Amedisys Company Profile

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer’s. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.